New inhaled drug aims to ease lung scarring and heart strain

NCT ID NCT06635850

Ongoing Disease control Sponsor: Pulmovant, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measures changes in blood vessel resistance in the lungs and how far people can walk in six minutes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mosliciguat (inhaled)
What this could lead to: If successful, this could lead to a new inhaled treatment to improve blood flow and exercise ability in people with lung scarring and high blood pressure in the lungs.
What could go wrong: This is an early Phase 2 trial with only 135 people, so results may not confirm benefit. The drug may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Fibrosis interstitial lung disease lung disorder pulmonary fibrosis pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES FIBROSIS INTERSTITIAL LUNG DISEASE LUNG DISEASES PULMONARY HYPERTENSION VASCULAR DISEASES

Contacts and locations

Locations

Arizona Pulmonary Specialists

Phoenix, Arizona, 85012, United States
Brown Medicine

East Providence, Rhode Island, 02915, United States
Duke University Health System - Duke Clinic

Durham, North Carolina, 27710, United States
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC

Celebration, Florida, 34746, United States
Harbor-UCLA Medical Center - Torrance

Torrance, California, 90502, United States
Houston Methodist Lung Center

Houston, Texas, 77030, United States
Hoxworth Blood Center

Cincinnati, Ohio, 45267, United States
Lewis Katz School of Medicine

Philadelphia, Pennsylvania, 19140, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Northwestern University

Chicago, Illinois, 60026, United States
Norton Pulmonary Specialists

Louisville, Kentucky, 40202, United States
PulmonIx

Greensboro, North Carolina, 27403, United States
Ronald Reagan UCLA Medical Center

Los Angeles, California, 90024, United States
Summit Health

Bend, Oregon, 97701, United States
University of California Davis School of Medicine

Sacramento, California, 95817, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Utah Health

Salt Lake City, Utah, 84132-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.